<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01096355</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-01550</org_study_id>
    <secondary_id>NCI-2011-01550</secondary_id>
    <secondary_id>CDR0000666959</secondary_id>
    <secondary_id>PMH-PJC-003</secondary_id>
    <secondary_id>PJC-003</secondary_id>
    <secondary_id>8501</secondary_id>
    <secondary_id>U01CA132123</secondary_id>
    <nct_id>NCT01096355</nct_id>
  </id_info>
  <brief_title>Gamma-Secretase Inhibitor RO4929097 in Treating Patients With Metastatic or Unresectable Solid Malignancies</brief_title>
  <official_title>A Phase I Study of Various Administration Schedules of RO4929097 With Multi-parameter Assessment (Biomarkers, Pharmacokinetics, Pharmacodynamics) in Patients With Advanced Solid Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects, best way to give, and best dose of&#xD;
      gamma-secretase inhibitor RO4929097 in treating patients with metastatic or unresectable&#xD;
      solid malignancies. Enzyme inhibitors, such as gamma-secretase inhibitor RO4929097, may stop&#xD;
      the growth of tumor cells by blocking some of the enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety profile of 6 different administration schedules of gamma-secretase&#xD;
      inhibitor RO4929097 in patients with advanced solid malignancies.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine pharmacokinetic (PK) parameters of gamma-secretase inhibitor RO4929097&#xD;
      administered using 6 different administration schedules.&#xD;
&#xD;
      II. To assess the preliminary antitumor activity of gamma-secretase inhibitor RO4929097 in&#xD;
      these patients.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the pharmacodynamic (PD) effects of gamma-secretase inhibitor RO4929097 on Notch&#xD;
      signaling pathway in tumor and surrogate tissues, as well as soluble markers of angiogenesis&#xD;
      in plasma, when administered using 6 different dosing schedules. (Exploratory) II. To&#xD;
      evaluate the relationship between PK and PD effects in an attempt to define the optimal&#xD;
      biological dosing schedule (OBDS) that can provide a sustained inhibition of Notch signaling&#xD;
      pathway over time with a tolerable toxicity profile. (Exploratory) III. To correlate&#xD;
      inhibition of Notch signaling pathway measured in tumor and surrogate tissues with&#xD;
      preliminary antitumor activity and assess the potential clinical predictive value of OBDS as&#xD;
      defined above. (Exploratory) IV. To assess the effect of the various pharmacogenomic&#xD;
      polymorphisms of the cytochrome P450 pathway on PK and PD parameters. (Exploratory)&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study. Patients are assigned to 1 of 6 dose&#xD;
      schedules.&#xD;
&#xD;
      GROUP A: Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3 and&#xD;
      8-10.&#xD;
&#xD;
      GROUP B: Patients receive oral RO4929097 once daily on days 1-7.&#xD;
&#xD;
      GROUP C: Patients receive oral RO4929097 once daily on days 1, 3, 5, 7, 9, 11, 13, 15, 17,&#xD;
      19, and 21.&#xD;
&#xD;
      GROUP D: Patients receive oral RO4929097 once daily on days 1, 8, and 15.&#xD;
&#xD;
      GROUP E: Patients receive oral RO4929097 once daily on days 1, 4, 8, 11, 15, and 18.&#xD;
&#xD;
      GROUP F: Patients receive oral RO4929097 once daily days 1-5, 8-12, and 15-19.&#xD;
&#xD;
      Treatment in all groups repeats every 3 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22&#xD;
      in the first course of treatment. Plasma samples are collected periodically for&#xD;
      pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of&#xD;
      adipsin and markers of angiogenesis.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety profile of six different administration schedules of RO4929097</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic profiles of various administration schedules</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary antitumor activity of RO4929097 assessed using RECIST 1.1 criteria</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters of RO4929097 administered using six different dosing schedules</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3 and 8-10.&#xD;
Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral RO4929097 once daily on days 1-7.&#xD;
Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral RO4929097 once daily on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21.&#xD;
Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral RO4929097 once daily on days 1, 8, and 15.&#xD;
Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral RO4929097 once daily on days 1, 4, 8, 11, 15, and 18.&#xD;
Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral RO4929097 once daily days 1-5, 8-12, and 15-19.&#xD;
Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gamma-secretase/Notch signalling pathway inhibitor RO4929097</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <other_name>R4733</other_name>
    <other_name>RO4929097</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic laboratory biomarker analysis</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacogenomic studies</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <other_name>Pharmacogenomic Study</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid malignancy&#xD;
&#xD;
               -  Metastatic or unresectable disease&#xD;
&#xD;
               -  Standard curative or palliative measures do not exist or are no longer effective&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1&#xD;
             dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or&#xD;
             as ≥ 10 mm with spiral CT scan&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  ECOG performance status (PS) 0-1 (Karnofsky PS 70-100%)&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Leukocytes ≥ 3,000/mm^3&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Total bilirubin normal&#xD;
&#xD;
          -  AST/ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Serum creatinine normal OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  No uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia, or&#xD;
             hypokalemia, defined as &lt; lower limit of normal despite adequate electrolyte&#xD;
             supplementation&#xD;
&#xD;
          -  QTc ≤ 450 msec in males and a QTc ≤ 470 in females, as measured by ECG using Bazett's&#xD;
             formula&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use 2 forms of contraception (i.e., barrier contraception and 1&#xD;
             other method of contraception) for ≥ 4 weeks before, during, and for ≥ 12 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  Willing to undergo 2 tumor biopsies (unless medically contraindicated)&#xD;
&#xD;
          -  Able to swallow medication&#xD;
&#xD;
          -  No malabsorption syndrome or other condition that would interfere with intestinal&#xD;
             absorption&#xD;
&#xD;
          -  No diarrhea ≥ grade 2 not under control with standard antidiarrhea medications&#xD;
&#xD;
          -  No uncontrolled concurrent illness including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia other than chronic, stable atrial fibrillation&#xD;
&#xD;
               -  Psychiatric illness or social situations that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
          -  No history of risk factors for QT interval prolongation including, but not limited to,&#xD;
             a family or personal history of any of the following:&#xD;
&#xD;
               -  Long QT syndrome&#xD;
&#xD;
               -  A history of torsades de pointes&#xD;
&#xD;
               -  Recurrent syncope without known etiology&#xD;
&#xD;
               -  Sudden unexpected death&#xD;
&#xD;
          -  Female patients may not donate ova during or after study treatment&#xD;
&#xD;
          -  No blood donation during and for ≥ 12 months after completion of study treatment&#xD;
&#xD;
          -  No serologic positivity for hepatitis A, B, or C; history of liver disease; or other&#xD;
             forms of hepatitis or cirrhosis&#xD;
&#xD;
          -  No HIV-positive patients on combination antiretroviral therapy&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to gamma-secretase inhibitor RO4929097 or other agents used in&#xD;
             this study&#xD;
&#xD;
          -  No other concurrent agents or therapies administered with the intent to treat the&#xD;
             patient's malignancy&#xD;
&#xD;
          -  No prior gamma-secretase inhibitors&#xD;
&#xD;
          -  Any number of prior treatment regimens allowed&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy or systemic therapy (6 weeks for prior&#xD;
             carmustine or mitomycin C)&#xD;
&#xD;
               -  Exceptions may be made for low-dose, nonmyelosuppressive radiotherapy for&#xD;
                  symptomatic palliation&#xD;
&#xD;
          -  Recovered from the adverse events due to prior therapy to &lt; CTCAE grade 2 (except&#xD;
             alopecia)&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent medications with narrow therapeutic indices that are metabolized by&#xD;
             cytochrome P450, including warfarin sodium (Coumadin®)&#xD;
&#xD;
          -  No concurrent medications that are strong inducers/inhibitors or substrates of CYP3A4&#xD;
&#xD;
          -  No concurrent medications or food that may interfere with the metabolism of&#xD;
             gamma-secretase inhibitor RO4929097 including ketoconazole, grapefruit, or grapefruit&#xD;
             juice&#xD;
&#xD;
          -  No antiarrhythmics or other concurrent medications with known potential to prolong QT&#xD;
             interval&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lillian Siu</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network-Princess Margaret Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BCCA-Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>March 30, 2010</study_first_submitted>
  <study_first_submitted_qc>March 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2010</study_first_posted>
  <last_update_submitted>April 1, 2014</last_update_submitted>
  <last_update_submitted_qc>April 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>R04929097</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

